Cargando…
Palifermin for management of treatment-induced oral mucositis in cancer patients
Oral mucositis (OM) remains a major side effect of various cancer therapies, which exacts a significant price in terms of morbidity and cost of care. Efforts aimed at prevention and/or therapy of OM have been largely unsuccessful. Few agents have shown efficacy, and even those were applicable to lim...
Autores principales: | Barasch, Andrei, Epstein, Joel, Tilashalski, Ken |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726051/ https://www.ncbi.nlm.nih.gov/pubmed/19707400 |
Ejemplares similares
-
Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis
por: Sonis, Stephen T
Publicado: (2010) -
Clinical applications of palifermin: amelioration of oral mucositis and other potential indications
por: Vadhan-Raj, Saroj, et al.
Publicado: (2013) -
Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case–control study
por: Lauritano, Dorina, et al.
Publicado: (2014) -
Emerging new clinical applications for palifermin: beyond its use in oral mucositis and graft versus host disease
por: Kapoor, Shailendra
Publicado: (2012) -
Efficacy of Palifermin in the Hematopoietic Stem Cell Transplant Setting
por: Panjwani, Muneera
Publicado: (2013)